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CASE REPORT
RHINOSCLEROMA: EIGHT PERUVIAN CASES
Ciro MAGUIÑA(1), Juan CORTEZ-ESCALANTE(3), Fernando OSORES-PLENGE(1), Jorge CENTENO(1), Humberto GUERRA(1),
Manuel MONTOYA(1), Jaime COK(2) & Cleudson CASTRO(3)
SUMMARY
Rhinoscleroma is a rare infection in developed countries; although, it is reported with some frequency in poorer regions such
as Central Africa, Central and South America, Eastern and Central Europe, Middle East, India and Indonesia. Nowadays,
rhinoscleroma may be erroneously diagnosed as mucocutaneos leishmaniasis, leprosy, paracoccidioidomycosis, rhinosporidiasis,
late syphilis, neoplasic diseases or other upper airway diseases. From 1996 to 2003, we diagnosed rhinoscleroma in eight patients
attended in the Dermatologic and Transmitted Diseases service of “Cayetano Heredia” National Hospital, in Lima, Peru. The
patients presented airway structural alterations producing nasopharyngeal, oropharyngeal and, in one patient, laryngeal stenosis.
Biopsy samples revealed large vacuolated macrophages (Mikulicz cells) in all patients. Ciprofloxacin 500 mg bid for four to 12
weeks was used in seven patients and oxytetracycline 500 mg qid for six weeks in one patient. After follow-up for six to 12 months
the patients did not show active infection or relapse, however, all of them presented some degree of upper airway stenosis. These
cases are reported because of the difficulty diagnosing the disease and the success of antibiotic treatment.
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INTRODUCTION
Rhinoscleroma is a slowly progressive, chronic and granulomatous
bacterial disease that usually affects the respiratory tract mucosa. Most
of the cases have been reported from poorer regions such as Central
Africa, Central and South America, Eastern and Central Europe, Middle
East, India and Indonesia. In recent years, some cases in non-endemic
areas were reported, explained by the increased migration of the
population over the world5. Rhinoscleroma is an ancient disease. It is
thought that it was frequent in the pre-Columbian Maya civilization in
Central America (300 to 600 years AD)20. In 1870, Ferdinand von Hebra
carried out a clear description of the disease; some years later, Johann
von Mikulicz considered that it was a inflammatory disease and
described the typical foamy cells (large histiocytes - Mikulicz cells).
In 1882, von Frisch identified the etiologic agent now known as
Klebsiella rhinoscleromatis29.
Three overlapping stages were described in rhinoscleroma:
Catarrhal-atrophic (sometimes called ozaena), granulomatous
(proliferative or nodular) and sclerotic (cicatricial or fibrotic). During
the catarrhal stage there are foul smelling purulent nasal discharges
and nasal obstruction; physical examination may demonstrate atrophy
and crusting of the nasal mucosa or hyperemia and exudates in the
respiratory tract mucosa. In the granulomatous stage there are epistaxis,
nasal deformity, hoarseness, anosmia and anesthesia of the soft palate;
physical examination may find a bluish red and rubbery granulomatous
lesion which evolves into a pale hard granulomatous mass. Sclerotic
stage symptoms are similar to the previous stage; on physical
examination the granulomatous lesions are surrounded by dense fibrotic
tissue. Most patients are diagnosed in the granulomatous stage, because
they are more symptomatic and other organs besides the nose may be
involved5.
At present, rhinoscleroma is a diagnostic and therapeutic challenge
due to its chronic course and need for prolonged treatment. In addition,
the disease may be mistakenly diagnosed as neoplasic disease,
mucocutaneos leishmaniasis, leprosy, paracoccidiodomycosis,
rhinosporidiasis, late syphilis, etc35.
Herein, we report eight cases of Rhinoscleroma from Peru and
review the main aspect of the disease.
PATIENTS AND METHODS
The patients were seen in the Dermatologic and Transmitted
Diseases and Otorhinolaryngologic services of “Cayetano Heredia”
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National Hospital from January 1996 to March 2003. All of them were
evaluated clinically and by nasopharyngolaryngoscopy. Samples were
collected for pathologic and microbiological examinations. Warthin
Starry and haematoxylin - eosin stains were used to examine the biopsy
samples. Histopathological findings were classified as follows: A)
Catarrhal - atrophic stage: squamous metaplasia, subepithelial infiltrate
of neutrophils and some granulation tissue. B) Granulomatous stage:
atrophy or hyperplasia, showing an infiltrate of chronic inflammatory
cells, monocytes, lymphocytes and histiocytes. “Mikulicz cells” could
be observed as large histiocytes with numerous vacuoles containing
viable or non-viable bacteria. “Russell bodies” were visualized as
eosinophilic structures within the cytoplasm of plasma cells. C)
Sclerotic stage: large amount of fibrous and cicatricial tissues and few
or no Mikulicz cells or Russell bodies. The histologic hallmark for
diagnosis of rhinoscleroma is the sub-epithelial presence of Mikulicz
cells. Patients were followed up for six months to one year.
RESULTS
Patients were born in different cities of Peru, although, seven of
them were living in Lima city for several years. The age range was 25
to 66 years and six (75%) were female. The most frequent symptoms
were purulent rhinorrhea (six, 75%), some degree of breathing difficulty
(five, 62.5%), nasal obstruction (four, 50%), disphony (four, 50%) and
facial pain (three, 37.5%). The symptomatic periods before diagnosis
were variable, from six months to 12 years. Endoscopy showed several
lesions, granulomatous infiltration in the choanas in four patients (50%),
larynx (three, 37.5%) and oropharynx (two, 25%), crusting (four, 50%)
and inflamed mucosal inside the nasal cavity (three, 37.5%), and
oropharynx (three, 37.5%). Three patients (37.5%) were found with X
ray opacity in the paranasal sinus. Histopathologically, six (75%)
patients were classified in the granulomatous, one in catarrhal and one
in sclerotic stages. Culture was positive in three patients in the
granulomatous stage, the isolates were Klebsiella rhinoscleromatis,
Klebsiella ozaenae and Klebsiella sp. Mikulicz cells were found in the
biopsies of all the patients. Ciprofloxacin, 500 mg bid, for four to 12
weeks (median of six weeks) was prescribed in seven patients and
oxytetracycline, 500 mg qid, for six weeks was used in one patient
(Table 1). After that, all patients had inactive infection during the follow-
up without any relapses. All, however, remained with some degree of
upper airway stenosis. After therapy, two patients developed other upper
respiratory tract infections by common germs several times and needed
additional antibiotics and surgical debridement.
The sixth patient was a pregnant woman who arrived to the
emergency service with cyanosis and acute respiratory distress, due to
laryngeal obstruction, and that needed an emergency tracheostomy.
DISCUSSION
The accepted of rhinoscleroma causative agent is Klebsiella
rhinoscleromatis, a Gram-negative rod-shaped bacteria with 2.5 µm in
length which, along with K. pneumoniae, K. ozaenae, K. oxytoca and
others, belong to the family Enterobacteriaceae. K. rhinoscleromatis
has a complex capsule cover and many fimbriae, which are responsible
for the microorganism’s ability to adhere to host cells33.
Rhinoscleroma always affects the respiratory tract and sometimes
involves other organs nearby. The nose is affected in 95% to 100% of
cases, often bilaterally and asymmetrically, the pharynx in 18% to
43%, larynx in 15% to 80%, trachea in 12%, and bronchi in 2% to
7%2,22,34. Other affected organs include the paranasal sinuses2,
eustachian tubes19, middle ear1, orbital tissues26, skin close to the
affected mucosas17, and the brain9. Our patients presented similar
frequencies; the nose was affected in 87.5%, pharynx in 50%, larynx
in 75% and trachea in 37.5%.
Humans are the only identified host of K. rhinoscleromatis23. This
bacterium is not a typical resident in the airway tract and the skin
microbiota, so that it has been isolated only from lesions of the human
airway mucosa14. Transmission results most probably through large
amount of contaminated airborne particles, which are expelled by
coughing and sneezing, or by contact with contaminated fomites22.
Several risk factors have been associated with rhinoscleroma. This
disease is more frequent among people in the second or third decades
of life, living in crowded conditions, rural areas, with poor hygienic
and nutritional conditions19 such as anemia for iron deficiency3 and in
women (female:male ratio is 13:1)21. The presence of K.
rhinoscleromatis is not enough for the development of the disease;
since contact for many years of a patient with healthy individuals may
not necessarily bring about the infection in the latter. This has led to
the suggestion that susceptibility of the host is important to develop
the disease18. Cellular immunity is probably impaired. Peripherally
there is a reduction in CD4+ lymphocytes and a significant elevation
in the numbers of CD8+ lymphocytes, so the CD4/ CD8 ratio into the
lesion is decreased, possibly inducing a diminished or altered T-cell
response10. The humoral immunity response does not control the
infection, probably due to the intracellular nature and copius mucin
coat of the bacteria, or due to the non specific nature antibody of the
response of the host. Whether these defects are acquired after infection
or already present in predisposed individuals remains uncertain24.
Chronicity of the disease is still not well understood. After mucosal
invasion by the bacteria, the acute inflammatory response is inefficient,
the neutrophils phagocityze Klebsiella, but appear to die too soon,
before digestion finishes, releasing viable bacteria. Histiocytes continue
with phagocytosis, and their phagosomes undergo massive dilatation.
They thus become Mikulicz cells, which are unable to destroy K.
rhinoscleromatis, and eventually rupture, releasing the bacteria into
the interstitium12. The altered proportion of CD4+ and CD8+
lymphocytes in the lesion may produce disabled macrophages, allowing
bacterial multiplication inside them and an ineffectual delayed type
hypersensitivity response23. K. rhinoscleromatis possess several
important resistance characteristics such as a complex capsule covered
by fimbriae, pleomorphism and the ability to grow vigorously both
intra and extracellularly12.
Specific diagnosis is made by the bacterial isolation by culture on
blood or MacConkey agar (positive in 50% to 60%) and by identification
of histopathologic features and bacillis in biopsied lesions biopsies,
using periodic acid-Schiff (PAS), Giemsa and Warthin - Starry stain5.
These stains combined with immunoperoxidase staining using
Klebsiella capsular type 3 antiserum increase accuracy and specificity
of both histological and bacteriological diagnoses29. Radiography,
computed tomography or resonance imaging rarely lead to diagnosis
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Table 1
Characteristics, clinical presentations and findings in the diagnostics procedures and treatment of eight patients with rhinoscleroma in Peru, assisted in “Cayetano
Heredia” national hospital from 1996 - 2003
Cases Age Time from Symptoms Paranasal X rays Culture Histopathologic
disease diagnosis Treatment
1 60 yr Female 10 yr Mucopurulent rhinorrhea, Diffuse opacity in K. rhinoscleromatis Granulomatous Ciprofloxacin,
cough with mucous all the paranasal 500 mg bid,
expectoration, dysphagia, sinuses for 12 weeks
hoarseness, foreign body
sensation in the pharynx
and laryngeal stridor.
2 30 yr Male 1 yr Foul smelling purulent — K. ozaenae Granulomatous Oxytetracycline,
rhinorrhea, slight breathing 500 mg qid,
difficulty due to nasal for six weeks
obstruction and sporadic
cough with expectoration.
3 31 yr Female 6 mo Purulent rhinorrhea, nasal Opacity of both Negative Catarrhal Ciprofloxacin,
obstruction, hyposmia and maxillary sinuses 500 mg bid,
slight morning facial pain. and right frontal for four weeks
sinus
4 34 yr Male 8 yr Foul smelling purulent Opacity of right Klebsiella sp. Granulomatous Ciprofloxacin,
rhinorrhea with nasal maxillary sinus 500 mg bid,
obstruction and slight for six weeks
breathing difficulty. Pain in
the infra-orbital region,
dysphonia and right otalgia.
5 25 yr Female 6 mo A sense of right nasal — Negative Granulomatous Ciprofloxacin,
obstruction and intranasal 500 mg bid,
tumor, deformation of the for six weeks
nasal pyramid, mild epistaxis
and, occasionally, frontal
headache.
6 30 yr Female 12 yr Cough with mucopurulent — Negative Granulomatous Ciprofloxacin,
expectoration, dysphonia, 500 mg bid,
larynx stridor, cyanosis and for six weeks
acute respiratory distress.
7 46 yr Female 5 yr Purulent nasal discharge, — Negative Sclerotic Ciprofloxacin,
slight breathing difficulty 500 mg bid,
and dysphonia. for eight weeks
8 66 yr Female 6 mo Dry cough, slight breathing — Negative Granulomatous Ciprofloxacin,
difficulty and dysphonia. 500 mg bid,
Without rhinorrhea. for five weeks
of rhinoscleroma, although they are helpful in defining the extension
of the disease25.
Rhinoscleroma treatment involves prolonged antibiotic therapy, in
the attempt to eradicate K. rhinoscleromatis, because the relapse rate
is high. In vitro, these bacteria are inhibited by clinically achievable
concentrations of amoxicillin - clavulanate, chloramphenicol,
trimethoprim - sulfamethoxazole, cephalosporins, streptomycin,
tetracyclines and ciprofloxacin32. However, in vivo, antibiotics with
demonstrated efficacy are streptomycin, doxycycline, tetracycline,
rifampicin, second- and third-generation cephalosporin, sulfonamides,
clofazimine, ciprofloxacin11 and ofloxacin31. Because K.
rhinoscleromatis is an intracellular bacteria prolonged courses of
rifampicin and fluroquinolones would theoretically be most effective,
due to their high concentration in macrophages22,37. BORGSTEIN et
al.(1993), reported that 89% of culture of the biopsy of the lesion was
negative two months after the use of ciprofloxacin for four weeks, and
after six months clinical improvement was significant and the relapse
rate was low11. However, the duration of antibiotic therapy with
ciprofloxacin has not been established, different author recommend
using for six weeks to six months or longer, until repeated cultures and
histological examination are negative30. Long-term follow-up is required
to identify early relapse8,22. Topical antibiotics such as acriflavine 2%
or rifampin have been used with significant results7,19. Most of our
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patients used ciprofloxacin 500 mg bid for a period of four to 12 weeks
with good results and no one relapsed during six to 12 months of follow-
up, which agrees with other reports from Latin America15,28.
Granulomatous tissue, crusting and fibrotic scarring are lesions
that produce several degrees of airway obstruction and cosmetic
deformity, so that surgical therapy is indicated in some cases36. Surgical
procedures must be postponed until no residual disease activity is
evident in the tissues to be debrided; otherwise there is high risk of
relapse or iatrogenic dissemination22. Carbon dioxide surgical laser
showed to be of value27. Tracheobronchial stenosis could be managed
by bronchoscopic dilatation13. Severe acute respiratory failure could
require emergency tracheostomy, close observation and oral or
intravenous corticosteroids4,38. Pregnant women could be a special group
affected with serious airway obstruction by granulomatous infiltration
into the laryngotracheal mucosa6. The only severe case in our report
was a pregnant woman with long-standing disease (12 years) involving
glottal stenosis who needed tracheostomy.
After therapy, patients remain with some sequels which vary in
seriousness that depend on the organs affected, such as hoarseness and
stridor because of glottal/subglottal stenosis, dysphonia due to fibrosis
of the vocal folds fibrosis, olfactory disorders produced by nasal mucosa
scarring. Early diagnosis and prolonged therapy are critical to avoid
their late sequelae4. Case fatality is extremely low in rhinoscleroma38.
Prophylaxis is based on the improvement of sanitary conditions
and general living conditions of poor people in endemic areas16.
CONCLUSION
Rhinoscleroma is a multifactorial disease with some identified risk
factors, more frequent in middle aged women, living in rural areas
with poor hygiene and nutritional conditions. Patients show a deficient
immuno-cellular response which could be acquired by the infection or
to other associated risk factor such as malnutrition, or could be
constitutional. It is a long-standing disease that begins in the nasal
mucosa and extends to other respiratory tract organs, producing airway
obstruction and sometimes threatens the patient life. Early diagnosis
and treatment are important to eradicate K. rhinoscleromatis and limit
the fibrotic scarring sequelae. Fluoroquinolones are well-tolerated drugs
with low incidences of adverse effects when used for long periods.
There is no evidence of relapse after quinolone treatment, indicating
that they are good therapy, although there have been no formal clinical
trials to evaluate their efficacy.
RESUMO
Rinoscleroma: oito casos peruanos
O rinoscleroma é uma infecção rara nos países desenvolvidos, no
entanto, tem sido relatado com alguma freqüência nas regiões pobres
da África Central, América Central e do Sul, Europa Central e Oriental,
Oriente Médio, Índia e Indonésia. A doença pode ser erroneamente
diagnosticada como leishmaniose mucocutânea, hanseníase,
paracoccidioidomicose, rinosporidiose, sífilis tardia, neoplasias ou
outras doenças que afetam a via respiratória superior. No período de
1996 a 2003, foram diagnosticados oito casos de rinoscleroma no
serviço de Doenças Dermatológicas e Infecciosas do Hospital Nacional
“Cayetano Heredia”, em Lima, Peru. Os pacientes apresentaram
alterações estruturais das vias respiratórias, caracterizadas por estenose
da nasofaringe e orofaringe, e em um paciente, a nível da laringe. As
biópsias mostraram macrófagos com grandes vacúolos (células de
Mikulicz). A ciprofloxacina 500 mg de 12/12 horas por quatro a 12
semanas foi usada em sete pacientes e oxitetraciclina 500 mg de 6/6
horas por seis semanas em um paciente. Durante o acompanhamento
por seis a 12 meses todos os pacientes apresentaram cura clínica, sem
recaída, embora exibissem algum grau de estenose na via respiratória
superior. O motivo do relato deve-se ao fato desta doença constituir
um grande desafio diagnóstico e pelo sucesso alcançado com o
tratamento antibiótico.
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